Genvor Incorporated Reports $429,567 Net Loss in Q2 Fiscal 2026, No Revenue Generated

Genvor Incorporated reported its financial results for the second quarter of fiscal year 2026, revealing a net loss of $429,567 for the three months ended March 31, 2026, compared to a loss of $298,983 during the same period in the previous year. For the six months ended March 31, 2026, the company recorded a net loss of $1,005,847, a significant reduction from the $5,300,234 loss reported in the prior year. The company did not generate any revenue during this period, maintaining a consistent trend from the previous fiscal year.

The company’s total operating expenses for the second quarter amounted to $407,492, up from $276,056 in the same quarter of the previous year. This increase was primarily driven by higher professional fees, which rose to $55,778 from $8,462, and increased compensation and related benefits, which totaled $253,361 compared to $189,390 in the prior year. Genvor's accumulated deficit as of March 31, 2026, reached $27,199,153, an increase from $26,193,306 at the end of the previous fiscal year.

In terms of strategic developments, Genvor has been actively engaged in product development and organizational changes. The company has focused on advancing its AI-accelerated peptide technology aimed at agricultural biologicals and human health. During the six months ended March 31, 2026, Genvor issued 1,586,666 shares of common stock for cash, raising $665,333, and also issued shares for various services and compensation, reflecting ongoing efforts to manage its capital structure and operational needs.

Operationally, Genvor's total current assets increased significantly to $176,762 as of March 31, 2026, from $45,822 at the end of the previous fiscal year, primarily due to an increase in cash and prepaid expenses. The company’s total liabilities remained stable at $1,067,857, down from $1,358,204, indicating a reduction in financial obligations. The company’s employee headcount and customer engagement metrics were not disclosed in the filing, but the management emphasized the importance of developing its product lines to enhance market presence.

Looking ahead, Genvor's management expressed intentions to raise additional funds through public and private offerings to support ongoing operations and product development. However, the company acknowledged substantial doubt about its ability to continue as a going concern, given its current cash position and the lack of revenue generation. The management remains optimistic about the potential for future growth and revenue generation as it continues to implement its business strategy and develop its technologies.